MedTrace Logo

Safety of Oral Anticoagulants Registry

NCT02745054 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2018-05-22

No results posted yet for this study

Summary

The goal of SOAR is to characterize the clinical and economic impact of clinicians' responses to major bleeding complications and pre-procedural concerns for bleeding risk in patients treated with oral anticoagulants (warfarin, anti-Xa orals, and anti-thrombin (IIa) orals) who present to the ED or in the hospital with acute illness or injury, with the eventual aim of informing the development of improved approaches to the management of OACs in the ED.

Conditions

  • Blood Coagulation

Interventions

OTHER

mgt of bleeding concerns/complications of oral anticoagulants

observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Daiichi Sankyo

    collaborator INDUSTRY

  • CSL Behring

    collaborator INDUSTRY

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Portola Pharmaceuticals

    collaborator INDUSTRY

  • Hospital Quality Foundation

    lead OTHER

Principal Investigators

  • Charles V Pollack, MD · Hospital Quality Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-08-31
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02745054 on ClinicalTrials.gov